Overview

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in subjects with plaque-type psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Galderma
Galderma R&D
Treatments:
Calcitriol